BanskotaS, RaguramA, SuhS, et al.Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell. 2022; S0092-8674(21)01484–7. DOI: 10.1016/j.cell.2021.12.021.
2.
KimS, KimD, ChoSW, et al.Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014; 24:1012–1019.DOI: 10.1101/gr.171322.113.
3.
ChewWL, TabebordbarM, ChengJKW, et al.A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods, 2016; 13: 868–874. DOI: 10.1038/nmeth.3993.
4.
GillmoreJD, GaneE, TaubelJ, et al.CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med, 2021; 385:493–502. DOI: 10.1056/NEJMoa2107454.
5.
FrangoulH, AltshulerD, Domenica CappelliniM, et al.CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021; 384:252–260. DOI: 10.1056/NEJMoa2031054.
6.
MangeotPE, RissonV, FusilF, et al.Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins. Nat Commun. 2019; 10:45. DOI: 10.1038/s41467-018-07845-z.
7.
HamiltonJR, TsuchidaCA, NguyenDN, et al.Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. Cell Rep. 2021; 35:109207. DOI: 10.1016/j.celrep.2021.109207.
8.
RichterMF, ZhaoKT, EtonE, et al.Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat Biotechnol. 2020; 38:883–891. DOI: 10.1038/s41587-020-0453-z.
9.
MusunuruK, ChadwickAC, MizoguchiT, et al.In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature, 2021; 593:429–434. DOI:
10.
ThorneRG, NicholsonC. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci U S A. 2006; 103:5567–5572. DOI: 10.1038/s41586-021-03534-y.
